Dominance of Targeted Therapies Over Traditional Chemotherapy
Targeted therapies are becoming the leading treatment modality in the Chronic Lymphocytic Leukemia Treatment Market, gradually overtaking chemotherapy and immunotherapy. According to MRFR, the market value reached USD 5.75 billion in 2024 and is expected to climb to USD 8.7 billion by 2032. Targeted agents such as BTK inhibitors (e.g., ibrutinib, acalabrutinib) and BCL-2 inhibitors (like venetoclax) are favored due to better tolerability, oral administration, and deep remissions. In contrast, chemo-based regimens—such as FCR (fludarabine, cyclophosphamide, rituximab)—are declining as the standard of care. Biologics including monoclonal antibodies and burgeoning CAR-T therapies also contribute meaningfully, especially in relapsed or refractory cases. This shift reflects a broader trend toward personalized and less toxic CLL treatments.